AIM To investigate the effect of Sofren Injection on myocardial cell morphology, cardiac function and ventricular remodeling in rats with heart failure.
METHODS Seventy-five SD male rats were selected, of whom 15 were randomly selected as a blank control group and 60 were treated intraperitoneally with doxorubicin (4 μg/g). After 6 weeks, LVEF was <60% in all animals. A heart failure model was established. The experiment group was divided into model control, low-dose, medium-dose, and high-dose Sofren Injection groups, with 15 rats in each group. 2ml/kg of Sofren Injection was injected into the tail vein once a day for 2 weeks and blank control group received normal daily saline. After 2 weeks, the echocardiographic index, RASS-related index and serum BNP level were assessed in all rats, and myocardial tissue morphology was observed. miRNA423-5p, miRNA499-5p, and miRNA210-3p were extracted from peripheral blood and their expressions were examined and compared with those of the healthy control rats.
RESULTS 6 ml/kg Sofren Injection lowered LVEDV and LVESV while increasing LVEF and LVFS. Injections of 6 ml/kg Rhodiolarosea reduced plasma levels of miR-210-3p, miR-423- 5p, miRNA-499 and BNP in heart failure model rats. 6 ml/kg Sofren Injection restored the RASS indexes of heart failure rats to the level of the normal group.
CONCLUSION Sofren Injection has the effect of inhibiting the excessive activation of RASS and improving cardiac function. miR-423-5P, miRNA-499 and miR-210-3P can be used as serum markers of CHF.
DownLoad: